Approval of both the protocol and the consent form must be obtained before any participant is enrolled. Any amendment to the protocol will require review and approval by the IRB before the changes are implemented to the study. In addition, all changes to the consent form will be IRB-approved; an IRB determination will be made regardin g whether a new consent needs to be obtained from participants who provided consent, using a previously approved consent form. 1. INTRODUCTION 1.1 S TUDY OBJECTIVES 1.1.1 Primary Objective • To evaluate the objective response rate (ORR) according to Response Evaluation Criteria (RECIST 1.1) of the combination of (1) a therapeutic vaccine against HPV positive cancers (PDS0101), (2) a tumor targeted immunocytokine NHS- IL12 (M9241) and (3) a bifunctional fusion protein targeting PD-L1 and TGF beta (M7824) in subjects with checkpoint naïve advanced HPV associated malignancies . 1.1.2 Secondary Objectives • To evaluate the safety of the combination of (1) a therapeutic vaccine against HPV positive cancers (PDS0101), (2) a tumor targeted immunocytokine NHS- IL12 (M9241) and (3) a bifunctional fusion protein targeting PD-L1 and TGF beta (M7824) in subjects with advanced HPV associated malignancies . • To assess progression -free survival time (PFS) according to RECIST 1.1.